...
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Alleviating the Hydrolysis of Carbohydrates, Tangzhiqing (TZQ) Decreased the Postprandial Glycemia in Healthy Volunteers: An Eight-Period Crossover Study
【24h】

Alleviating the Hydrolysis of Carbohydrates, Tangzhiqing (TZQ) Decreased the Postprandial Glycemia in Healthy Volunteers: An Eight-Period Crossover Study

机译:缓解碳水化合物的水解,唐芝卿(TZQ)减少了健康志愿者的餐后糖血症:八期交叉研究

获取原文
           

摘要

Tangzhiqing (TZQ), a Chinese herbal medicine, has been widely used to treat diabetes mellitus in China. TZQ works as a potential α-glucosidase inhibitor to reduce the absorption of glucose from dietary carbohydrates. The main aim of this study was to investigate the postprandial glucose-lowering effect of TZQ on the common carbohydrates in healthy humans. Meanwhile, the possible types of the inhibited α-glucosidase enzymes were predicted in this study. Glucose, sucrose, maltose, maltodextrin, and starch were chosen as investigated carbohydrates. The baseline incremental area under the curve (IAUC) and glycemic index (GI) values of the investigated carbohydrates were evaluated. Then, thirty-six subjects were randomly assigned to three groups to assess postprandial hypoglycemic effects of 3-, 6-, and 9-tablet TZQ. The subjects in each group were randomized to eight subgroups. An eight-period, eight-sequence, crossover design was performed to investigate the postprandial glucose-lowering effect of TZQ after drinking each carbohydrate. A significant decrease was observed on the postprandial glucose IAUCs (279.41?±?111.31 vs. 203.86?±?61.08) and GIs (124.91?±?48.54 vs. 91.69?±?27.47) of maltose after oral administration of 6-tablet TZQ, as well as IAUCs (145.05?±?55.01 vs. 110.23?±?57.03) and GIs (84.87?±?33.40 vs. 65.50?±?33.89) of sucrose after administration of 3-tablet TZQ. The glucose IAUCs (109.15?±?55.92 vs. 57.68?±?46.09) and GIs (49.09?±?25.15 vs. 25.94?±?20.73) of starch statistically reduced following the administration of 6-tablet TZQ. The lowering postprandial blood glucose effect of TZQ did not increase proportionally with increasing doses in humans. There were no significant changes in the glucose-lowering effect of glucose and maltodextrin after the administration of 3-, 6-, or 9-tablet TZQ, respectively. TZQ is a potential treatment for postprandial hyperglycemia, which can probably make α-glucosidases inhibit maltase, sucrase, and α-amylase in the digestive organs.
机译:中国草药(TZQ)唐志清(TZQ)已被广泛用于治疗中国的糖尿病。 TZQ作为潜在的α-葡糖苷酶抑制剂,以减少膳食碳水化合物的葡萄糖的吸收。本研究的主要目的是研究TZQ对健康人类常见碳水化合物的后葡萄糖降低效果。同时,在该研究中预测了可能类型的抑制α-葡糖苷酶。选择葡萄糖,蔗糖,麦芽糖,麦芽糖糊精和淀粉作为所研究的碳水化合物。评估所研究的碳水化合物的曲线(IAC)和血糖指数(GI)值下的基线增量区域。然后,将三十六个受试者随机分配给三组,以评估3-,6-和9片TZQ的餐后低血糖作用。每组的受试者随机分为八个亚组。进行八个八个六个序列的交叉设计,以研究饮用每种碳水化合物后TZQ的后葡萄糖降低效果。在口服6平板电脑后,对餐后葡萄糖IAC(279.41±±111.31与203.86?±48.54〜91.69?±27.47)麦芽糖(124.91?±48.54)和GIS以及IACS(145.05?±55.01 vs.110.23?±57.03)和GIS(84.87?±33.40〜65.50〜±33​​.40〜65.50°+ 33.89),蔗糖3-片剂TZQ后蔗糖的蔗糖。葡萄糖IACs(109.15?±55.92与57.68?±46.09)和GIS(49.09?±25.15 vs.25.94?±20.73)淀粉统计学上减少6平板电脑TZQ后。随着人类中的剂量增加,TZQ的降低后血糖效应不会比例增加。葡萄糖和麦芽糖糊精的葡萄糖和麦芽糖糊精分别在施用3-,6-或9平片TZQ后没有显着变化。 TZQ是对餐后高血糖的潜在治疗,其可能使α-葡糖苷酶抑制消化器官中的麦芽糖酶,蔗糖酶和α-淀粉酶。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号